As of April 2020, the estimated prevalence of anti-SARS-CoV-2 Igs in the general population was 0.23% [9], although higher percentages were sporadically recorded in overpopulated or SARS-CoV-2-exposed niches, due to differences in infection rates [10]. This evidence concerns the gene CUBN and infection.